Geode Capital Management LLC Boosts Holdings in Solventum Corporation $SOLV

Geode Capital Management LLC raised its holdings in shares of Solventum Corporation (NYSE:SOLV) by 20.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,588,728 shares of the company’s stock after purchasing an additional 763,308 shares during the period. Geode Capital Management LLC’s holdings in Solventum were worth $362,375,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SOLV. Independent Franchise Partners LLP increased its holdings in Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its stake in shares of Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after purchasing an additional 1,272,921 shares during the last quarter. Boston Partners boosted its stake in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares during the last quarter. Finally, Davis Selected Advisers boosted its stake in shares of Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares during the last quarter.

Insider Buying and Selling

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.24% of the company’s stock.

Solventum Trading Up 1.4%

NYSE SOLV opened at $75.97 on Tuesday. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20. The company’s 50 day moving average price is $69.75 and its 200 day moving average price is $75.08. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a market capitalization of $13.16 billion, a price-to-earnings ratio of 9.31, a PEG ratio of 1.16 and a beta of 0.59.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the firm posted $1.34 earnings per share. Solventum’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. KeyCorp raised their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. Wells Fargo & Company decreased their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Wedbush assumed coverage on shares of Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.